重视钠-葡萄糖共转运蛋白2抑制剂相关肾损伤的防范与监管  

Pay attention to the prevention and supervision of kidney injury related to sodium⁃glucose trans⁃porter 2 inhibitors

作　　者：纪立伟[1] Ji Liwei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Drug Clinical Risk and Personalized Medica-tion Evaluation,Beijing 100730,China)

机构地区：[1]北京医院药学部/国家老年医学中心/中国医学科学院老年医学研究院/北京市药物临床风险与个体化应用评价重点实验室,北京100730

出　　处：《药物不良反应杂志》2025年第3期142-146,共5页Adverse Drug Reactions Journal

摘　　要：钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是目前临床使用广泛的一类降糖药,因其独特的降糖机制和显著的心肾保护作用,成为2型糖尿病治疗的核心药物之一。但近年来发现SGLT2i可导致部分患者血肌酐和尿素氮增高,相关肾损伤的风险逐渐引起临床的关注。如何在充分发挥其治疗优势的同时,有效防范和监管其潜在的肾损伤风险,成为当前临床实践和药物安全管理的重要课题。临床需采取多维度防范与监管策略,如基于最新证据识别高危人群、严格筛选治疗人群、动态监测肾功能及优化联合用药方案、借助生物标志物与人工智能工具实现风险预警。Sodium-glucose transporter 2 inhibitors(SGLT2i)are currently widely used as a class of hypoglycemic drugs.Due to their unique hypoglycemic mechanism and significant cardio-renal protective effect,SGLT2i have become one of the core drugs in the treatment of type 2 diabetes mellitus.However,in recent years,it has been found that SGLT2i can lead to increased serum creatinine and urea nitrogen in some patients,and the risk of kidney injury has gradually attracted clinical attention.How to effectively prevent and supervise the potential renal injury risk while giving full play to its therapeutic advantages has become an important topic in current clinical practice and drug safety management.Multi-dimensional prevention and supervision strategies should be adopted in clinical practice such as identifying high-risk populations based on the latest evidence,strictly screening patients,dynamically monitoring renal function,optimizing combination medication regimens,and achieving risk warning using biomarkers and artificial intelligence tools.

关 键 词：钠-葡萄糖共转运蛋白2抑制剂 急性肾损伤 糖尿病 2型 心力衰竭 慢性肾脏病 药物警戒 人工智能 

分 类 号：R97[医药卫生—药品] R969[医药卫生—药学]